Capital Analysts LLC
MIRA icon

Capital Analysts LLC’s MIRA Pharmaceuticals MIRA Stock Holding History

Capital Analysts LLC’s Portfolio MIRA Stock Details MIRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$156 Hold
165
– – ﹤0.01% 1557
2026
Q1 		$177 Hold
165
– – ﹤0.01% 1574
2025
Q4 		$249 Buy
+165
New +$242 ﹤0.01% 1478

Other funds holding MIRA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CSI
Cross Staff Investments Pittsford, New York $168M AUM 14.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $67.2B AUM 18.61% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
First American Bank
First American Bank Dundee, Illinois $1.81B AUM 24.18% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Capital Analysts LLC's MIRA Position: Q2 2026 in Review

Capital Analysts LLC held its MIRA Pharmaceuticals (MIRA) position steady in Q2 2026 at 165 shares worth $156. The position accounts for ﹤0.01% of the portfolio, ranked #1557.

Capital Analysts LLC first reported a position in MIRA in Q4 2025 and has held it in 3 quarters since. The position peaked at $249 in Q4 2025. 27 funds tracked by Wall St. Rank hold MIRA as of Q2 2026.

  • Capital Analysts LLC held 165 shares of MIRA Pharmaceuticals worth $156 as of Q2 2026.
  • Capital Analysts LLC left its MIRA Pharmaceuticals share count unchanged in Q2 2026.
  • MIRA Pharmaceuticals made up ﹤0.01% of Capital Analysts LLC's portfolio in Q2 2026, its #1557 holding.
  • Capital Analysts LLC first reported a position in MIRA Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Capital Analysts LLC's MIRA Pharmaceuticals position peaked at $249 in Q4 2025.
  • 27 funds tracked by Wall St. Rank held MIRA Pharmaceuticals as of Q2 2026.

Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.